Table 1 Demographics and baseline disease characteristics relevant to Psoriatic Arthritis Disease Activity Score
Characteristic mean (SD) unless otherwise stated | Secukinumab 300 mg s.c. (N = 100) | Secukinumab 150 mg s.c. (N = 100) | Placebo (N = 98) |
|---|---|---|---|
Age, years | 46.9 (12.6) | 46.5 (11.7) | 49.9 (12.5) |
Female, n (%) | 49 (49.0) | 45 (45.0) | 59 (60.2) |
Time since diagnosis of PsA in years | 7.4 (7.5) | 6.5 (8.2) | 7.3 (7.8) |
TNFi-naïve, n (%) | 67 (67.0) | 63 (63.0) | 63 (64.3) |
Psoriasis ≥ 3% of BSA, n (%) | 41 (41.0) | 58 (58.0) | 43 (43.9) |
Physician’s global VAS | 55.0 (14.7) | 56.7 (16.6) | 55.0 (16.0) |
Patient’s global VAS | 60.7 (18.9) | 62.0 (19.5) | 57.6 (19.8) |
SF-36 PCS | 36.9 (8.0) | 36.2 (8.1) | 37.4 (8.8) |
Dactylitis counta | 3.6 (3.5) | 4.5 (5.1) | 2.7 (2.2) |
Enthesitis countb | 2.8 (1.7) | 3.2 (16) | 3.1 (1.7) |
TJC (78 joints) | 20.2 (13.3) | 24.1 (19.4) | 23.4 (19.0) |
SJC (76 joints) | 11.2 (7.8) | 11.9 (10.1) | 12.1 (10.7) |
PASDAS score | 5.9 (0.9); n = 98 | 6.0 (1.0); n = 99 | 5.8 (1.0); n = 98 |